Butin inhibits osteoarthritis progression by modulating the Nrf2/HO-1 signaling pathway and inhibiting NF-κB signaling Authors: Ping Zhou, Jun Chang, Xiaofei Wei, Chengxin Zhu, Junjun Yang, Chao Wang, Yong Hu, Chi Zhang Published: 2025 ABSTRACT AbstractThe current treatment of osteoarthritis is limited to the reliever treatment of anti-inflammatory drugs, and there is still a lack of safe and effective drug treatment. Butin, a flavonoid, has the potential to be a drug candidate due to its excellent anti-inflammatory and antioxidant effects. However, the molecular mechanism of Butin’s anti-inflammatory and antioxidant mechanisms is still unclear, so in this study, we explored Butin’s role in alleviating osteoarthritis and the role of Butin in regulating the Nrf2/HO1/NF-κB axis of cellular antioxidant defense. We used the MTT test, the EdU test, and flow cytometry (FCM) to validate Butin’s effect on IL-1β-induced chondrocyte cell viability. Western blot (WB) was used to detect the Nrf2/HO1/NF-κB axis-related proteins to explore the effect of Butin on the Nrf2/HO1/NF-κB axis. In addition, we used quantitative real-time polymerase chain reaction (qPCR), Elisa, flow cytometry to detect cartilage extracellular matrix characteristic proteins (Aggrecan, Collagen II, MMP13 and ADAMTS5). The results showed that Butin could effectively up-regulate the Nrf2/HO1 axis, reduce NF-κB expression, improve chondrocyte damage, and alleviate the progression of osteoarthritis.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-26243-2.Subject terms: Biochemistry, Cell biology, Diseases, Drug discovery, Molecular biology Introduction Osteoarthritis (OA) is one of the most prevalent joint disorders worldwide, affecting approximately 528 million individuals and often accompanied by pain and functional impairment, especially in the elderly, although younger patients may also be affected1. OA primarily involves weight-bearing joints and is characterized by progressive degeneration of articular hyaline cartilage. As the disease advances, patients develop pronounced cartilage erosion, subchondral bone sclerosis, joint-space narrowing, and osteophyte formation, together with localized inflammation manifesting as swelling and pain2,3. Current therapeutic approaches rely largely on anti-inflammatory agents for symptomatic relief and, in late-stage disease, on replacement arthroplasty, wherein a prosthesis is used to substitute the degenerated joint structure(4). Consequently, the identification of candidate drugs with genuine disease-modifying potential in OA is of considerable clinical importance. Accumulating evidence indicates that excessive accumulation of reactive oxygen species (ROS) and the ensuing oxidative stress play pivotal roles in the initiation and progression of OA within chondrocytes4–6. Elevated ROS levels not only disrupt cartilage metabolic homeostasis but also upregulate matrix-degrading enzymes—such as matrix metalloproteinases7 (MMPs) and aggrecanases8—thereby reducing synthesis of key extracellular matrix components, including type II collagen (COL2A1)9. Moreover, ROS modulate multiple signaling pathways, exacerbating inflammation, metabolic imbalance, and apoptosis, all of which drive OA pathogenesis10–12. Thus, pharmacological targeting of these critical signaling cascades represents a promising strategy for mitigating and treating OA. Emerging evidence indicates that nuclear factor erythroid 2–related factor 2 (Nrf2), a master transcription factor, plays a crucial protective role in osteoarthritis by regulating cellular antioxidant defenses under oxidative stress13,14. The Nrf2/heme oxygenase-1 (HO-1) axis is a classical antioxidant signaling pathway that controls the expression of phase II detoxifying enzymes and is intimately linked to the apoptotic machinery15–17. Activation of this pathway has been shown to markedly reduce oxidative damage and apoptosis in chondrocytes. In contrast, NF-κB serves as a central mediator of inflammation in various pathological conditions, including OA, particularly during the initiation of pro-inflammatory cytokines such as IL-1α, IL-1β, and IL-6. Upon IL-1β stimulation, rapid degradation of IκBα liberates NF-κB dimers, facilitating their nuclear translocation and triggering a cascade of inflammatory gene expression. ROS and NF-κB signaling engage in complex bidirectional crosstalk: inflammatory signaling elevates intracellular ROS levels, while ROS can both enhance and inhibit NF-κB activity via multiple mechanisms12,18. Importantly, activation of the Nrf2/HO-1 pathway not only promotes efficient ROS clearance but also counteracts NF-κB–mediated inflammatory responses, providing a dual protective effect19,20. Therefore, pharmacological strategies that simultaneously activate Nrf2/HO-1 signaling and inhibit NF-κB pathways hold promise as novel approaches to attenuate cartilage degeneration in osteoarthritis. Butin is a naturally occurring flavonoid with significant antioxidant and anti-inflammatory properties21,22. The phenolic hydroxyl group in its structure is the key to its pharmacological activity, which can scavenge free radicals and reduce oxidative stress-induced mitochondrial dysfunction and mitochondria-dependent apoptosis. Butin can also inhibit the release of inflammatory mediators to achieve anti-inflammatory. However, there are few studies on the relevant mechanisms in Butin mitochondrial protection. Therefore, we examined whether Butin improves osteoarthritic chondrocyte injury via modulation of the Nrf2/HO-1 pathway and inhibition of NF-κB signaling. Materials and methods Reagents and instruments Butin (purity > 98%, 72795, purchased from Sigma Company). Methyl-thiazolyl-tetrazolium assay (MTT) (M158055, Sigma Company). DCFH-DA (H131224, Sigma Company). Antibodies: Nrf2 (16396-1-AP), HO-1 (10701-1-AP), p-IkBα (82335-1-RR), p65 (10745-1-AP), Lamin B (12987-1-AP), and β-actin (20536-1-AP). (All antibody were purchased from Wuhan Proteintech Biotechnology Co., LTD). Elisa: Cyclin B1 (SPS-22650) was purchased from Saipeisen Biology. Cyclin D1 (RX202555M), CDK1 (RX200167M), PGE2 (RXJW202688M), TNF-α (RX202412M), and IL-6 (RXQ248) was purchased from Ruixin Biotech. Aggrecan (JL53549-48T), Collagen II (JL11584-48T), and MMP13 (JL12015-48T) was purchased from Jonlnbio. ADAMTS5(JLC-Y6072) was purchased from Gelatins. Microscope (Leica Microsystems, Wetzlar, Germany), microplate reader (BioTek Instruments, Winooski, VT, USA), Western blot electrophoresis system (Bio-Rad Laboratories, Hercules, CA, USA). Cell culture Eight 7-day-old mice (C57BL/6, males) were anesthetized with pentobarbital to death. Under aseptic conditions, dissect the articular cartilage, cut it up with micro scissors and incubate with 1% type II collagenase (2 mg/mL) for 4 h at 37 °C. The digested cartilage was then resuspended in PBS, centrifuged and cultured in DMEM/F12 (Gibco, NY, USA) dishes containing 10% fetal bovine serum and 1% strep tomycin/penicillin antibiotics. Primary chondrocytes were passaged to 2–3 generations for follow- up experiments. The incubator was maintained in a humid atmosphere with 5% CO2 at 37 °C. Cell proliferation assay The methyl-thiazolyl-tetrazolium assay (MTT) was used to detected cell viability. Rat chondrocytes were seeded into 96-well plates at a density of 1 × 104 cells/well and cultured for 12 h. The cells were then treated by IL-1β and/or Butin according to the experi mental design. After appropriate treatment, cells were incubated with MTT solution (20 µL) for 4 h. The absorbance was determined with a microplate reader (Infinite M200 pro, TECAN, Switzerland) at 570 nm. Cells in the 6-well plate were stained with EdU and PI/Annexin V, and analyzed by flow cytometry. Intracellular ROS detection DCFH-DA fluorescent probe was used to detect the effect of Butin on intracellular ROS levels in chondrocytes. After different treatments, chondrocytes were incubated with DCFH-DA at a concentration of 10 µM for 20 min under dark. After PBS washing (3 times, 5 min each), the chondrocytes were then analyzed by flow cytometry. ELISA analysis Cells were seeded in 96-well plates at a density of 4 × 103 cells/well in 100 µL culture medium and allowed to adhere for 24 h at 37 °C. After treatment with different methods, the medium was removed and replaced with fresh medium containing ELISA detection reagents(Shanghai Keshun Biotechnology Co., LTD, including cyclin D1 KS12938, clclin B1 KS13550, iNOS KS12466, TNF-α KS10484, IL-6 KS12523. Wuhan Finetest Biotechnology Co., LTD, including PEG2 EM1503, Aggrecan EM0695, Collagen II EM2237, MMP13 EM0303, and ADAMTS5 ER1808). Following the treatment period, cell lysates were prepared and analyzed according to the manufacturer’s protocol. Absorbance measurements were taken at 450 nm using a microplate reader (Bio-Rad, CA). The experiment was performed in triplicate across three independent trials to ensure data reproducibility. Protein activity and expression levels were quantified based on the measured absorbance values. Western blot analysis Cells were rinsed with PBS and lysed using RIPA buffer supplemented with protease and phosphatase inhibitors. The lysates were centrifuged at 12,000 × g for 10 min at 4 °C, and the supernatants were collected and stored at −80 °C for further analysis. Protein concentrations were determined using a BCA Protein Assay Kit, following the manufacturer’s guidelines. Equal amounts of protein (20 µg) were separated on a 12% SDS-PAGE gel and subsequently transferred to a PVDF membrane. The membrane was blocked with 5% skimmed milk in TBST for 1 h at room temperature. The membranes were probed with primary antibodies (including Nrf2, HO-1, p-p65, p65, p-IkBa, IkBa, β-actin, Lamin B, The antibody dilution ratio was 1:1000, and the antibodies were purchased from Wuhan Proteintech Biotechnology Co., LTD) targeting overnight at 4 °C. After washing with TBST, the membranes were incubated with species-specific horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 h at room temperature. Following three washes with TBST, protein bands were visualized using an ECL Detection Kit. The chemiluminescent signals were captured, and GAPDH was used as an internal control for normalization. Animal model Forty-five 8-week-old C57BL/6 male wild-type (WT) mice were obtained from the Shanghai Animal Center, Chinese Academy of Sciences. The OA mouse model was established by surgically destabilizing the medial meniscus after anesthesia via intraperitoneal injection of 2% (w/v) pentobarbital (40 mg/kg), as described previously (Glasson, Blanchet, and Morris 2007). The mice were randomly divided into Sham, DMM and DMM + Butin groups. Then, each mouse in the DMM + Butin group was intra-articularly injected with 20 µL of 250 µM Butin (50 µM non-toxic to chondrocytes according to CCK- 8 results) once a week for 8 weeks. Correspondingly, mice in the sham-operated and DMM groups were injected intra-articularly with 20 µL of PBS containing 0.1% DMSO. Mice in each group were euthanized via pentobarbital overdose 8 weeks after OA surgery, and the knee joints were dissected and treated for histological evaluation. The investigators were unaware of group assignments during the experiment and when assessing the results. Statistical analysis Data were expressed as mean ± standard error (SEM), and all data were evaluated for normality using the Shapiro-Wilk test and for homogeneity of variance using the Levene test prior to ANOVA; nonparametric tests were used for data that did not meet the prerequisites, all pairwise comparisons were initially conducted using one-way ANOVA (when variance homogeneity and normality were met), followed by Tukey’s HSD for post-hoc analysis. When performing multiple correlation tests (e.g., involving multiple biochemical indicators), we applied Benjamini-Hochberg FDR correction to control the family error rate. For data that did not meet ANOVA prerequisites, Kruskal-Wallis and Dunn post-tests were employed with multiple comparison adjustments. The significance level was set at p < 0.05. The Graphpad Prism 10.0.1 software was used to collect data. The ImageJ software was used to analyze fluorescence data. Result The effect of butin on the viability of IL-1β-treated chondrocytes To investigate the effects of Butin on inflammatory infiltrated chondrocytes, we first employed the MTT assay to examine the viability changes of IL-1β-treated chondrocytes under different concentrations of Butin. We found that the changes in chondrocyte viability exhibited a concentration-dependent relationship with Butin (Fig. 1A). At the same time, we found that with the gradual increase of Butin concentration, the proliferation rate of chondrocytes was limited, which means that high doses of Butin may have potential cytotoxicity. Concurrently, we measured chondrocyte viability at various time points under different treatments, and the results demonstrated that Butin effectively enhanced the viability of IL-1β-treated chondrocytes. Moreover, high-dose Butin (100µM) treatment nearly restored chondrocyte viability to normal levels (Fig. 1B). The effect of Butin on the viability of IL-1β-treated chondrocytes. (A) Cytotoxicity assay of different concentrations of Butin and (B) different time points across various groups. (C) EdU assay evaluating the impact of different treatment groups on chondrocyte proliferation. (D) PI/Annexin V assay for detecting apoptosis in different treatment groups. (E-F) ELISA detection of cell proliferation-related indicators. Data are presented as mean ± standard error of the mean (SEM) with n = 12 per group. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001. The statistical significance was obtained using a one-way ANOVA. Subsequently, to assess the impact of Butin on chondrocyte proliferation, we conducted EdU assays to evaluate cell division across different treatment groups. The findings revealed that Butin-treated groups exhibited fewer cells arrested in the G0 and G1 phases compared to the IL-1β-treated group (Fig. 1C). Flow cytometry analysis using PI/Annexin V staining indicated that Butin treatment reversed IL-1β-induced apoptosis (Fig. 1D). Additionally, we utilized ELISA to measure proliferation-related proteins (Cyclin D1, Cyclin B1, CDK1), which further corroborated the experimental results. The Butin-treated groups showed corresponding increases in these proliferation-related proteins (Fig. 1E-G). The effect of butin on the inflammatory level of IL-1β-treated chondrocytes The anti-inflammatory capacity of drugs is also a crucial indicator for osteoarthritis treatment. To validate the anti-inflammatory effect of Butin, we first employed qPCR to examine the expression levels of inflammation-related genes (iNOS, COX2, TNF-α, IL-6) in chondrocytes subjected to different treatment conditions (Figs. 2A-D). The results demonstrated that the experimental groups treated with Butin exhibited a significant reduction in inflammation-related markers, with higher doses of Butin showing more pronounced effects. Building upon these findings, we further utilized ELISA to assess the expression of inflammation-related proteins (PGE2, TNF-α, IL-6) (Figs. 2E-G). The outcomes aligned with the aforementioned results, indicating that Butin-treated groups displayed decreased expression of inflammatory proteins. Effect of Butin on the inflammatory level of IL-1β-treated chondrocytes. (A-D) qPCR detection of the expression of inflammation-related genes, including iNOS, COX2, TNF-α, and IL-6, after treatment in different groups. (E-G) ELISA detection of inflammation-related indicators, including PGE2, TNF-α, and IL-6, after treatment in different groups. Data are presented as mean ± standard error of the mean (SEM) with n = 12 per group. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001. The statistical significance was obtained using a one-way ANOVA. The effect of butin on IL-1β-Stimulated ECM degradation and senescence in chondrocytes The extracellular matrix (ECM) contains numerous supportive and protective substances for chondrocytes, including aggrecan and collagen II. During the progression of osteoarthritis, the ECM undergoes continuous aging and degradation. Therefore, effectively delaying the aging and degradation of the ECM is one of the indicators for evaluating the efficacy of osteoarthritis treatment. To investigate this, we first utilized qPCR to measure the expression of ECM-related genes (Aggrecan, Collagen II, MMP13, and ADAMTS) in chondrocytes under different treatments. The results showed that the expression levels of Aggrecan and Collagen II increased after Butin treatment, while the expression of MMP13 and ADAMTS decreased (Fig. 3A-D). This suggests that the aging and degradation of the ECM were delayed. The effect of Butin on IL-1β-stimulated ECM degradation and senescence in chondrocytes. (A-D) qPCR was used to detect the expression of ECM proliferation-related genes, including Aggrecan, Collagen II, MMP13, and ADAMTS5. (E-G) ELISA was employed to measure the protein expression levels of the aforementioned genes. Data are presented as mean ± standard error of the mean (SEM) with n = 12 per group. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001. The statistical significance was obtained using a one-way ANOVA. To further validate the expression of related proteins, we employed ELISA to assess the levels of Aggrecan, Collagen II, MMP13, and ADAMTS. The results were consistent with the aforementioned findings (Fig. 3E-H). Butin’s effect on the Nrf2/HO-1 axis and NF-κB signaling in IL-1β-treated chondrocytes After confirming the effective anti-inflammatory and injury-protective effects of Butin, we further investigated the potential mechanisms underlying these results. First, we utilized Western blotting (WB) to examine the expression levels of proteins related to the Nrf2/HO-1 axis under different treatment conditions. We found that in groups treated with Butin, the levels of Nrf2 and HO-1 proteins were significantly increased. However, the addition of siRNA Nrf2 attenuated this effect, clearly demonstrating Butin’s role in modulating the Nrf2/HO-1 axis. Additionally, we validated the expression of NF-κB signaling-related proteins, and the results showed that NF-κB signaling-related proteins were suppressed upon Butin treatment, further confirming the molecular mechanism of Butin’s anti-inflammatory properties (Fig. 4A). The ratios of Nrf2/β-actin, HO-1/β-actin, nuclear p65/Lamin B, p-IκBα/IκBα, and p-p65/p65 were measured using ImageJ software (Figs. 4B-F), providing additional validation for the aforementioned findings. Effects of Butin on the Nrf2/NF-κB pathway in IL-1β-treated chondrocytes. (A) Activation status of the Nrf2/HO-1 axis and NF-κB/p65 axis after different treatment groups. (B-F) Grayscale value statistics of protein expression for the aforementioned signaling pathways. Data are presented as mean ± standard error of the mean (SEM) with n = 12 per group. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001. The statistical significance was obtained using a one-way ANOVA. Butin alleviates IL-1β-induced inflammatory injury in chondrocytes through the Nrf2/HO-1 axis and NF-κB signaling pathway After verifying the aforementioned molecular mechanisms, we examined the inflammatory markers in the treated chondrocytes. First, we utilized qPCR to detect iNOS, COX2, TNF-α, and IL-6. The results demonstrated that the anti-inflammatory effect of Butin was inhibited upon the addition of siRNA Nrf2, which corroborates the above findings (Fig. 5A-D). Meanwhile, ELISA results further confirmed that the anti-inflammatory effect of Butin is mediated through the Nrf2/HO-1 axis (Fig. 5E-H). Butin alleviates IL-1β-induced inflammatory injury in chondrocytes via the Nrf2/NF-κB pathway. (A-D) ELISA detection of inflammation-related gene expression levels including iNOS, COX2, TNF-α, and IL-6 after treatment in different groups. (E-G) ELISA detection of ECM-related indicators including Aggrecan, Collagen II, MMP13, and ADAMTS5 after treatment in different groups. Data are presented as mean ± standard error of the mean (SEM) with n = 12 per group. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001. The statistical significance was obtained using a one-way ANOVA. Evaluation of Anti-inflammatory effects in butin in vivo Encouraged by the in vitro experimental results, we proceeded to validate the findings through in vivo experiments. First, the experimental groups were divided into the sham group, DMM group, and DMM + Butin group. Butin treatment was administered once a week, and after eight consecutive weeks, the mice were euthanized. Joint tissues were first harvested, and Western blot (WB) was used to examine the expression of the Nrf2/HO-1 axis, as well as the NF-κB signaling pathway (Fig. 6A). Additionally, Image software was employed to quantify the ratios of Nrf2/β-actin, HO-1/β-actin, nuclear p65/Lamin B, p-IκBα/IκBα, and p-p65/p65 (Fig. 6B-F). The results were consistent with the in vitro experiments, demonstrating that Butin treatment upregulated the expression of Nrf2 and HO-1 proteins in the joint tissues while suppressing NF-κB signaling proteins. The effect of Butin in vivo on improving inflammatory damage in chondrocytes. (A) Activation status of the Nrf2/HO-1 axis and NF-κB/p65 axis after different treatment groups. (B-F) Statistical analysis of grayscale values for protein expression in the aforementioned signaling pathways. (G-I) ELISA detection of inflammation-related indicators after different group treatments, including PEG2, TNF-α, and IL-6. (J-M) ELISA detection of ECM proliferation-related gene expression, including Aggrecan, Collagen II, MMP13, and ADAMTS5. Data are presented as mean ± standard error of the mean (SEM) with n = 12 per group. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001. The statistical significance was obtained using a one-way ANOVA. Furthermore, ELISA was performed to measure the expression of inflammatory proteins. The results indicated that in the Butin-treated group, the levels of PGE2, COX2, and IL-6 were significantly reduced (Fig. 6G-I). Concurrently, the joint tissue exhibited a notable increase in aggrecan and collagen II, accompanied by a decrease in MMP13 and ADAMTS5. These findings suggest that Butin treatment effectively suppressed osteoarthritis-related inflammation and delayed the degeneration and degradation of the extracellular matrix (ECM) (Fig. 6J-M). Discussion In recent years, flavonoids have caused a research boom in many fields such as anti-inflammatory23, antioxidant24, wound healing25, etc. As one of the flavonoids, Butin’s role in the field of anti-inflammatory has also been continuously explored. Current studies have shown that Butin has good anti-inflammatory properties21, but the deeper molecular mechanisms are still unclear. Nuclear factor erythrocyte 2-related factor 2 (Nrf2) is a master transcription factor that plays a vital protective role in osteoarthritis by modulating cellular antioxidant defenses in response to oxidative stress. The Nrf2/heme oxygenase 1 (HO1) axis is a classic antioxidant signaling pathway, and activation of this pathway has been shown to significantly reduce oxidative damage and apoptosis in chondrocytes26–28. In contrast, NF-κB acts as a central mediator of inflammation in a variety of pathological conditions, including OA, especially during the priming of pro-inflammatory cytokines such as IL1α, IL1β, and IL6. Upon IL1β stimulation, rapid degradation of IκBα releases NF-κB dimers, promotes their nuclear translocation and triggers a cascade of inflammatory gene expression29,30. ROS and NF-κB signaling are involved in complex bidirectional crosstalk: inflammatory signaling increases intracellular ROS levels, while ROS can enhance and inhibit NF-κB activity through multiple mechanisms12,31. Therefore, effectively activating the Nrf2/HO1 axis and reducing the expression of NF-κB is one of the effective measures to promote cartilage injury in osteoarthritis. Considering Butin’s anti-inflammatory properties, in this study, we focused on whether Butin can regulate the Nrf2/HO1 axis and reduce the expression of NF-κB, thereby improving chondrocyte damage and alleviating chondrocyte extracellular matrix (ECM) aging and degradation. The above experimental results show that Butin can effectively alleviate the oxidative stress damage induced by IL-1β and reduce the infiltration of inflammatory components in the ECM by up-regulating the Nrf2/HO1 axis and decreasing the expression of NF-κB. At the same time, the experimental group of siRNA Nrf2 further showed that the effect of Butin is realized through the Nrf2/HO1 axis. In vivo experiments have also demonstrated Butin’s effective chondrocyte protective effect. Overall, our study clarified the molecular mechanism by which Butin alleviates chondrocyte damage. This is similar to the anti-inflammatory effect of existing flavonoids by regulating inflammatory related pathways32,33. However, the current experiments are still insufficient in terms of the molecular mechanism of Butin in the treatment of osteoarthritis, such as whether Butin can improve the infiltration of inflammatory cells or immune cells at the site of inflammation, and the evidence for whether Butin acts on the Nrf2/HO1 axis directly or through other pathways or related proteins is still unclear. For example, Shi et al. demonstrated that vitamin K can be used as an anti-ferroptosis drug to treat osteoarthritis34. Zhang et al. found that Acetyl zingerone can promote chondrocyte mitophagy through the PINK1/Parkin pathway, thereby alleviating osteoarthritis progression35. In addition, the limited histological evidence and animal models in this study greatly limit the clinical translation of the drug. In summary, these findings may provide a new perspective for Butin’s treatment of osteoarthritis. Further research on Butin may lead to a breakthrough in the treatment of osteoarthritis. Conclusion Overall, this study demonstrated that Butin can reverse IL-1β-induced chondrocyte damage, and that this reversal effect is positively correlated with Butin concentration and time. In further exploring the molecular mechanism, we found that Butin inhibited the expression of NF-κB by upregulating the Nrf2/HO1 axis, thereby improving the oxidative stress state of chondrocytes, while alleviating the aging and degradation of ECM and reducing the secretion of inflammatory factors. The siRNA Nrf2 experiment further confirmed the above molecular mechanism. Therefore, Butin provides a new perspective for the treatment of osteoarthritis by upregulating the Nrf2/HO1 axis and reducing the expression of NF-κB. This increases the clinical translational power of flavonoids, especially Butin, in the treatment of osteoarthritis. It gives clinical drug development a new potential direction. However, there are still some limitations in this study, such as whether Butin can alleviate osteoarthritis progression through other mechanisms or acting on certain key proteins, whether there is drug tolerance, and the evaluation of multi-drug synergistic effects. At the same time, the systematic evaluation and toxicological verification of biosafety in Butin have not yet been clarified. Further research is needed on these results. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Author contributions Ping Zhou and Jun Chang provided ideas and experimental methods. Xiaofei Wei and Chengxin Zhu performed the experiments and drafted the manuscript. Yong Hu assisted in literature review and data analysis. Chao Wang created tables and pictures for the article. Chi Zhang provided financial support and reviewed the manuscript. All authors have read and agree with the manuscript. Funding This study was supported financially by Natural science fund for colleges and universities in Anhui Province (2023AH050624), Research Fund of Anhui Institute of translational medicine (2022zhyx-C62). The Scientific Research Fund of Anhui Medical University (2023xkj172), Health research Project of Anhui Province in 2024(AHWJ2024Aa30352). The funding agency was not involved in any aspects of the study design, including data collection, interpretation of data or manuscript preparation. Data availability The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Competing interests The authors declare no competing interests. Ethics approval and consent to participate Our study was approved by the Institutional Animal Care and Use Committee of Anhui Medical University (LLSC20232175) and confirmed that all methods were performed in accordance with ARRIVE guidelines and other relevant guidelines and regulations. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. These authors contributed equally to this work: Ping Zhou and Jun Chang. Contributor Information Yong Hu, Email: hy.in163@163.com. Chi Zhang, Email: zc163official@163.com. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.